Showing 3711-3720 of 5154 results for "".
- ACR Study: Belimumab Improves CLE Toohttps://practicaldermatology.com/news/acr-study-belimumab-improves-cle/2461423/The B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE), according to research presented at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, Beli
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermati
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Happy 30th Birthday NRS!https://practicaldermatology.com/news/happy-30th-birthday-nrs/2461410/The National Rosacea Society (NRS) is celebrating its 30th anniversary in 2022. The past three decades have seen tremendous progress toward fulfilling our mission of improving the lives of people with rosacea through awareness, education and support of medical research.
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- New Aveeno Report Reveals 71% of Adults Have Sensitive Skinhttps://practicaldermatology.com/news/new-aveeno-report-reveals-71-of-adults-have-sensitive-skin/2461401/The Aveeno brand has launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a v
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th